In the latest trading session, 1.04 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched 0.71. With the company’s most recent per share price at $3.26 changed hands at -$0.16 or -4.68% at last look, the market valuation stands at $2.38B. IBRX’s current price is a discount, trading about -223.01% off its 52-week high of $10.53. The share price had its 52-week low at $2.28, which suggests the last value was 30.06% up since then.
Analysts gave the ImmunityBio Inc (IBRX) stock a consensus recommendation rating of Sell, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IBRX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ImmunityBio Inc’s EPS for the current quarter is expected to be -0.13.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX was in red as seen in intraday trades today. With action -9.94%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 27.34%, with the 5-day performance at -9.94% in the red. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is 4.49% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 45.67% from its recent market value. According to analyst projections, IBRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -84.05% plunge from its current level, while the stock would need to soar -84.05% for it to hit the projected low.
ImmunityBio Inc (IBRX) estimates and forecasts
Year-over-year growth is forecast to reach 3,312.86% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 9.51M. 2 analysts are of the opinion that ImmunityBio Inc’s revenue for the current quarter will be 23.09M. The company’s revenue for the corresponding quarters a year ago was 139k and 40k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 6,738.31%. The estimates for the next quarter sales put growth at 57,618.75%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.17%. The 2025 estimates are for ImmunityBio Inc earnings to increase by 30.43%, but the outlook for the next 5-year period is at 32.58% per year.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.6978% or 11.42 million shares worth $72.19 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 5.72 shares estimated at $18.47 million under it, the former controlled 0.82% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 0.71% of the shares, roughly 4.98 shares worth around $16.07 million.
